Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 19/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL28722159 | 1.00 | WNT3A (0.51) | WNT3AHRH4 | |
| Trifluoroacetic Acid SCHEMBL18453923 | 0.96 | WNT3A (0.49) | WNT3A | |
| SCHEMBL29557360 | 0.93 | WNT3A (0.50) | WNT3A | |
| SCHEMBL18453164 | 0.88 | WNT3A (0.53) | WNT3A | |
| Trifluoroacetic Acid SCHEMBL28708393 | 0.87 | DEGS1 (0.43) | WNT3AHRH4 | |
| Trifluoroacetic Acid SCHEMBL29544489 | 0.87 | DEGS1 (0.43) | WNT3AHRH4 | |
| Trifluoroacetic Acid SCHEMBL18453160 | 0.85 | CDK6 (0.46) | HRH4 | |
| Trifluoroacetic Acid SCHEMBL18453950 | 0.82 | WNT3A (0.49) | WNT3AHRH4 | |
| Trifluoroacetic Acid SCHEMBL28713633 | 0.81 | EP300 (0.46) | — | |
| Trifluoroacetic Acid SCHEMBL29543815 | 0.81 | EP300 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398132-B2 | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2025-08-26 | — | — | US | disclosed |
| US-20220259203-A1 | DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2022-08-18 | — | — | US | disclosed |
| EP-3997088-A1 | DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS | Aucentra Therapeutics Pty Ltd (AU) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259203-A1 | DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS | FLT3, CDK2, CDK4 | WNT3A 2672/4885HRH4 2674/4885 |
| US-12398132-B2 | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | FLT3, CDK2, CDK4 | WNT3A 2733/4885HRH4 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.